Telix Pharmaceuticals' quarterly report shows a strong revenue contribution from its acquired nuclear medicine business RLS ...

Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

Telix Pharmaceuticals has reaffirmed its full-year revenue guidance after posting strong first-quarter growth generated from ...

The first patient was dosed in the Phase 1 ZOLAR 7 trial of TLX300-CDx ( 89 Zr-olaratumab), which aims to validate the use of olaratumab, an antibody exclusively licensed from Eli Lilly and Company ...

We are pleased to be building upon our successful relationship to bring the accuracy and clinical utility of gallium-based imaging to even more patients across the country with Gozellix®.” ...

Telix Pharmaceuticals Ltd (ASX: TLX) shares are on the move after the ASX 200 biotech stock released its first quarter ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Cardinal Health (NYSE:CAH) has been selected as a distributor for Telix Pharmaceuticals' Gozellix®, an important development ...

The pipeline includes promising candidates like Gozellix, Zircaix, and Pixclara, targeting prostate, kidney, and brain cancers, with potential multi-billion dollar market opportunities.

To support the rollout, Cardinal Health has deployed Telix’s ARTMS QUANTM Irradiation System® (QIS®) cyclotron technology, enabling standardized, high-efficiency and cost-effective production of ...